Fifty-five, pensionless and assuming he’d have to work until he died, Roger Ulrich had a decision to make. After two decades in the pharmaceutical industry, his position at Merck & Co. had been phased out.
Potash Corp. of Saskatchewan Inc.’s decision to cut 18 percent of its workforce and reduce capacity probably foreshadows similar actions by North American rivals amid a price war in the $20 billion global potash market.
Johnson & Johnson officials destroyed or misplaced documents related to its vaginal-mesh implants and should be barred from relying on some defenses in planned trials over the devices, patients’ lawyers said.
A gauge of U.S. company credit risk was little changed. Johnson & Johnson, the AAA rated maker of health-care products from Band-Aids to Listerine, sold $3.5 billion of bonds in its first offering since 2011.
Canada’s bid to become what Prime Minister Stephen Harper calls an energy “superpower” is at risk as approval delays for new pipelines threaten an industry already hurt by high costs and rival production.
Johnson & Johnson may pay as much as $1 billion to insurers who covered the medical costs of removing its recalled hip implants under a settlement announced last week, according to a lawyer involved in the accord.
A New Jersey judge warned of several “rogue websites” by lawyers seeking to take advantage of Johnson & Johnson’s agreement to pay at least $2.47 billion to settle thousands of lawsuits over its recalled hip implants.